Gallium Nitrate for Acute Treatment of Cancer-related Hypercalcemia: Clinicopharmacological and Dose Response Analysis1

نویسندگان

  • Raymond P. Warrell
  • Anastasia Skelos
  • Nancy W. Alcock
  • Richard S. Bockman
چکیده

Current treatment of cancer-related hypercalcemia is limited by agents of limited effectiveness or excessive toxicity. Gallium nitrate is a new drug which both inhibits bone résorptionand increases calcium content of bone. We have now treated 39 episodes of hypercalcemia with gallium nitrate administered as a continuous i.v. infusion for 5-7 days at 3 daily dose levels (100 and 200 mg/m2, and 50 mg/m2 by brief infusion followed by 150 mg/m2). Nadir calcium values were significantly lower (9.2 ±1.5 mg/dl) for patients who received the highest dose relative to patients who received the lowest dose (10.5 ±1.6 mg/dl, /' < 0.001). While the actual percentage of patients who achieved normocalcemia was higher at the highest dose relative to the lowest dose (86 versus 60%), this difference was not statistically significant. Mean serum concentration of inorganic phosphorous declined significantly for all patients from 2.9 ±0.86 mg/ dl at base line to 1.8 ±0.66 mg/dl (/' < 0.001). Pharmacokinetic studies suggested that a threshold plasma gallium concentration of approximately I /Ji4ml must be attained to achieve acute normalization of elevated serum calcium levels. Steady-state plasma gallium levels were attained after 48 h; there was no evidence of drug accumulation in plasma after 2 days. Kffects on serum creatinine concentration were negligible, and there were no other toxic reactions. These data confirm preclinical experiments which suggested that inhibition of bone résorptionby gallium nitrate is dependent upon the dose and duration of drug exposure. We conclude that gallium nitrate is effective treatment for cancer-related hypercal cemia. The drug is now being evaluated against standard treatment in a randomized, double-blind trial.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Gallium nitrate for acute treatment of cancer-related hypercalcemia: clinicopharmacological and dose response analysis.

Current treatment of cancer-related hypercalcemia is limited by agents of limited effectiveness or excessive toxicity. Gallium nitrate is a new drug which both inhibits bone resorption and increases calcium content of bone. We have now treated 39 episodes of hypercalcemia with gallium nitrate administered as a continuous i.v. infusion for 5-7 days at 3 daily dose levels (100 and 200 mg/m2, and ...

متن کامل

Effect of gallium nitrate on tamoxifen induced hypercalcemia in rats bearing mammary tumor.

AIM To study the effect of gallium nitrate in the treatment of flare hypercalcemia in rats, bearing mammary tumor with bone metastasis. MATERIALS AND METHODS Female Sprague-Dawley albino rats were used in the study. Animals were divided into 5 groups: normal control; hypercalcemic rats bearing DMBA-induced mammary tumors; flare hypercalcemic animals bearing DMBA-induced mammary tumors (hyperc...

متن کامل

Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia.

Hypercalcemia complicates the course of 10%-30% of all patients with malignancies and can be a sign of very poor prognosis and advanced malignancy. Prompt recognition of the nonspecific signs and symptoms of hypercalcemia and institution of therapy can be lifesaving, affording the opportunity to address the underlying etiology. The mechanisms of malignancy-associated hypercalcemia generally fal...

متن کامل

Cancer-induced hypercalcemia.

Cancer-induced hypercalcemia (CIH) occurs in 5% to 30% of patients with cancer during the course of their disease, depending on the type of tumor. This review provides information on the pathophysiology and treatment of CIH. Enhanced bone resorption is the primary cause of CIH and the release of tumor-derived mediators induces this increase in osteoclast-mediated resorption. The interactions be...

متن کامل

A prospective radiobiological study of acute esophagitis and swallowing dysfunction in head-and-neck radiotherapy

Introduction: Esophagitis is one of the main causes of swallowing dysfunction after radiation therapy (RT) for head and neck cancer (HNC).It significantly affects patients’ quality of life as well as having a potentially negative impact on their long term survival. However, little has been investigated on the dose-response and normal tissue complication probability (NTCP) of es...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2006